Trial Profile
A double-blind comparative study of HP-5070 in patients with primary hyperhidrosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Hyperhidrosis
- Focus Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 01 Nov 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2018 New trial record